Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

• Ngā kaituhi matua: Jiawei Zhao (Author), Yong Tao (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

BackgroundTeprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post-marketing adverse events (AEs). In this study, we...